<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04097067</url>
  </required_header>
  <id_info>
    <org_study_id>UKM01_2019</org_study_id>
    <nct_id>NCT04097067</nct_id>
  </id_info>
  <brief_title>ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma</brief_title>
  <official_title>Phase II Trial to Assess the Efficacy of Low Radiation Dose of 20 Gy for the Treatment of Marginal Zone Lymphoma or Follicular Lymphoma Stage I-II Localized in the Stomach or the Duodenum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Lymphoma Radiation Oncology Group (ILROG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Muenster</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies the effectivity of low-dose radiation therapy with 10x2Gy for the
      treatment of patients with stage I-II stomach or duodenal Lymphoma (Marginal Zone or
      Follicular)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Prove the effectiveness of 20 Gy (and non-inferiority to actually recommended 30 Gy)
           with respect to response rate 6 months after radiotherapy.

        -  Correlation of blood serum biomarker levels with lymphoma response to radiation
           treatment

        -  Recording of survival rates, quality of life (QoL), radiogenic toxicities and
           inflammation relevant molecules in blood serum.

      Primary Objective:

      Response rate 6 months after end of treatment, 4 categories according to GELA-criteria: CR
      (complete remission) = CR or pMRD (probable minimal residual disease), PR (partial remission)
      = rRD (responding residual disease), NC (no change), PD (progressive disease)

      Secondary Objectives:

      QoL according to EORTC (QLQ C30 and STO22). EFS=Event-free survival (time to any failure or
      death from any cause, patients in CR or PR), LSS=lymphoma-specific survival (time to death
      related to lymphoma or associated with the treatment, all patients), PFS=Progression-free
      survival (time to progression of lymphoma or death from any cause, all patients), OS=overall
      survival (time to death from any cause, all patients). Level of cytokines IL-1β, IL-4, IL-8,
      TNFalpha and other inflammation relevant molecules Syndecan1, MMP-2 and S100 proteins. Acute
      toxicities during treatment according to NCI-CTC, chronic toxicities according to NCI-CTC/
      LENT-SOMA.

      Monitoring of Adverse Events (AEs) and Serious Adverse Events (SAEs)

      -Assessment of safety: Monitoring of Adverse Events (AEs) and Serious Adverse Events (SAEs)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>Until 6 months after end of treatment</time_frame>
    <description>4 categories according to GELA-criteria: CR (complete remission) = CR or pMRD (probable minimal residual disease), PR (partial remission) = rRD (responding residual disease), NC (no change), PD (progressive disease)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>QoL #1</measure>
    <time_frame>Until 6 months after end of treatment</time_frame>
    <description>According to QLQ C30 (EORTC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL #2</measure>
    <time_frame>Until 6 months after end of treatment</time_frame>
    <description>According to STO22 (EORTC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EFS</measure>
    <time_frame>Until at least 6 months after end of treatment</time_frame>
    <description>Event-free survival (time to any failure or death from any cause, patients in CR or PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LSS</measure>
    <time_frame>Until at least 6 months after end of treatment</time_frame>
    <description>Lymphoma-specific survival (time to death related to lymphoma or associated with the treatment, all patients)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>Until at least 6 months after end of treatment</time_frame>
    <description>Progression-free survival (time to progression of lymphoma or death from any cause, all patients)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>Until at least 6 months after end of treatment</time_frame>
    <description>Overall survival (time to death from any cause, all patients)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of cytokines in blood serum</measure>
    <time_frame>Until 6 months after end of treatment</time_frame>
    <description>IL-1β, IL-4, IL-8, TNFalpha and other inflammation relevant molecules Syndecan1, MMP-2 and S100 proteins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and chronic toxicities</measure>
    <time_frame>Until at least 6 months after end of treatment</time_frame>
    <description>Acute toxicities during treatment according to NCI-CTC, chronic toxicities according to NCI-CTC/ LENT-SOMA</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">83</enrollment>
  <condition>Follicular Lymphoma (Gastric or Duodenal)</condition>
  <condition>Marginal Zone Lymphoma (Gastric or Duodenal)</condition>
  <arm_group>
    <arm_group_label>Treatment (low-dose radiation therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo low-dose radiation therapy with daily 2 Gy ad 20 Gy (ISRT with IMRT &amp; IGRT).
Blood draw for biomarker-analysis (at baseline visit/ after 4 Gy/ after 10 Gy / after 20 Gy RT/ at 3 and 6 months after RT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Low dose radiotherapy with 20 Gy (10x2Gy)</description>
    <arm_group_label>Treatment (low-dose radiation therapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  primary indolent gastric or duodenal lymphoma

          -  pathology: marginal zone lymphoma (MZL) or follicular lymphoma (FL)

          -  stage: clinical stage I or II (Ann Arbor classification)

          -  H. pylori negative or antibiotic resistant lymphoma

          -  IPI or FLIPI score low - high (0-4)

          -  any size of tumor or affected lymph nodes

          -  male or female with age ≥ 18 years

          -  performance status ECOG 0 - 3

          -  written informed consent by the patient

        Exclusion Criteria:

          -  prior radiation treatment of the gastrointestinal lymphoma

          -  stage: clinical stage III or IV (Ann Arbor classification)-unability to understand the
             informed consent or unwillingness to participate in the study

          -  severe comorbidity or organ dysfunction contraindicating the use of RT (liver
             cirrhosis Child-Pugh C, chronic obstructive pulmonary disease GOLD 4, heart
             insufficiency NYHA IV, dialysis dependent renal insufficiency, uncontrolled epilepsy)

          -  known seropositivity for HIV

          -  acute hepatitis B or C infection

          -  chronic inflammatory bowel disease

          -  prior malignant disease (exclusion: basalioma, non-metastasized solid tumor in
             constant remission diagnosed &gt;3 years ago)

          -  pregnancy or breastfeeding

          -  active substance abuse or severely compromised compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Dr. H. Th. Eich</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Radiation Oncology University Hospital Muenster</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. G. Reinartz</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Radiation Oncology University Hospital Muenster</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gabriele Reinartz, MD</last_name>
    <phone>+492518347358</phone>
    <email>gabriele.reinartz@ukmuenster.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandra Lammers</last_name>
    <phone>+492518347358</phone>
    <email>Study.Radiooncology@ukmuenster.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Radiation Oncology</name>
      <address>
        <city>Münster</city>
        <state>North Rhine-Westphalia</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriele Reinartz, MD</last_name>
      <phone>+492518347358</phone>
      <email>gabriele.reinartz@ukmuenster.de</email>
    </contact>
    <contact_backup>
      <last_name>Stephan Rehn, MD</last_name>
      <phone>+492518347358</phone>
      <email>stephan.rehn@ukmuenster.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 17, 2019</study_first_submitted>
  <study_first_submitted_qc>September 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2019</study_first_posted>
  <last_update_submitted>September 19, 2019</last_update_submitted>
  <last_update_submitted_qc>September 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>Lymphoma, B-Cell, Marginal Zone</keyword>
  <keyword>Neoplasms by Histologic Type</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Lymphoproliferative Disorders</keyword>
  <keyword>Lymphatic Diseases</keyword>
  <keyword>Immunoproliferative Disorders</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>Lymphoma, B-Cell</keyword>
  <keyword>Lymphoma, Non-Hodgkin</keyword>
  <keyword>Lymphoma, follicular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

